Bladder carcinogenesis remains unclear despite the identification of chemical, environmental and genetic factors. It has recently been reported that the chromosomal region 12q13-q15, containing crucial cancer genes such as MDM2, CDK4 and GLI, is amplified in bladder cancer. In the same region are also located the genes of the locus HOX C, flanked by keratin genes whose protein product may be a prognostic marker of bladder cancer. The HOX genes constitute a network of transcription factors controlling embryonal development and play an important role in crucial adult eukaryotic cell functions. The molecular organization of this 39-gene network is unique in the genome and probably acts by regulating phenotypical cell identity. We have analysed the expression of the whole HOX gene network in pairs of normaltumour bladder and in tumoral biopsies. Comparison between normal urothelium and bladder tumour has identified dramatic variations of expression in a block of three genes (HOX C4, HOX C5 and HOX C6) localized in the HOX C locus on the chromosome 12q13 and in the paralogous group 11 HOX genes, involved during normal development in the formation of the urogenital system. These data suggest a key involvement of the HOX gene network, and especially the locus C, in bladder cancer.
Introduction
Various chromosomal and genetic abnormalities have been identified in bladder cancer (usually transitional cell carcinoma or TCC) (Sandberg, 2002) ; an initial event on chromosome 9 (9p21 and 9p34), although the specific genes involved are still unidentified, causes the highest mutation index detectable in TCC (CordonCardo, 1998) . Subsequent gene events involve both oncosuppressor genes linked to apoptosis and the cell cycle, such as p53 mutations on chromosome 17 (Fujimoto et al., 1992) and Rb on chromosome 13 (Wada et al., 2000) , and oncogenes involved in signal transduction, such as Ras (Shinohara and Koyanagi, 2002) . Besides these hot spots, other chromosomal sites on chromosome 7 (EGFR) (Gazzaniga et al., 2001) , chromosome 3 (RAF-1) (Simon et al., 2001) , chromosome 8 (C-MYC, FGFR-1) (Christoph et al., 1999; Simon et al., 2001 ) and other chromosomes are often involved in bladder cancer (Sandberg, 2002) . Moreover, epigenetic events of gene amplification lead to hyperexpression of crucial TCC genes, and comparative genomic hybridization (CGH) has recently made it possible to report the amplification of the chromosomal region 12q13-15 (Simon et al., 2002) . Finally, a transcription factor linked to embryonal development (PAX 5) and displaying oncogenic properties is localized in a key position (chromosome 9p13) in bladder carcinogenesis and seems to play an important role in TCC when inappropriately expressed (Adshead et al., 1999) .
Homeobox genes are transcription factors that act during normal development (Gehring and Hiromi, 1986) and contain the homeobox, a 183-bp DNA sequence coding for a 61-amino-acid homeodomain (HD). Different HD types or classes may be identified (Duboule and Morata, 1994) , each characterizing a homeobox gene family. Among these, the HD of the homeotic gene of Drosophila Antennapedia (Antp) defines a consensus sequence referred to as class I HD or Hox genes (Akam, 1987) . In mice (Hox genes) and humans (HOX genes), there are at least 39 genes organized in four genomic clusters of about 100 kb in length, defined as Hox loci, each localized on a different chromosome (HOX A at 7p15.3, HOX B at 17p21.3, HOX C at 12q13.3 and HOX D at 2q31) (Apiou et al., 1996) and comprising from 9 to 11 genes ( Figure 1 , right-hand side). On the basis of sequence similarity and position on the locus, corresponding genes in the four clusters can be aligned with each other and with genes of the HOM-C complex of Drosophila in 13 paralogous groups (Scott, 1992) . During mammalian development, Hox gene expression controls the identity of various regions along the body axis, from the branchial area through to the tail (Graham et al., 1989) . This is achieved according to the rules of temporal and spatial colinearity, with 3 0 Hox genes expressed early in development and controlling anterior regions, followed by more 5 0 genes progressively expressed later and controlling more posterior regions (Dekker et al., 1992) . The HOX gene network, the most repeat-poor regions of the human genome (Lander et al., 2001) , is also expressed in normal adult human organs (Cillo, 1994-95) . Hox and homeobox genes appear to regulate normal development, cell differentiation (Magli et al., 1991; Cantile et al., 2003b) and control other cellular processes, as proven by the recent description of congenital (Mortlock and Innis, 1997), somatic (Nakamura et al., 1996) , metabolic (Ferber et al., 2000) and neoplastic alterations (Gromova et al., 1999; Cillo et al., 2001; Abate-Shen, 2002 ) involving these genes.
In the present paper, we study the expression of the HOX gene network in 15 pairs of bladder biopsies obtained from patients with TCC and of specific HOX genes in 15 isolated TCCs. Each pair is made up, according to the pathologist, of normal urothelium and bladder cancer tissue (TCC) from the same individual. Results show that most of the genes in the HOX network are characteristically active in normal bladder. Some HOX genes are altered in their expression in bladder cancer. In particular, the genes at the 3 0 end of locus C, HOX C4, HOX C5 and HOX C6, belonging to the same transcription unit (Simeone et al., 1988) , seem to be silent in normal bladder and actively expressed in bladder cancer in the majority of cases analysed. The HOX C locus is located on the chromosome 12q13, within a chromosomal region amplified in the TCC and flanked at both the 5 0 and the 3 0 ends by keratin genes, which may be prognostic markers for TCC. Finally, the paralogous group 11 HOX genes (HOX A11, HOX C11 and HOX D11), already involved in the embryonal development of the urogenital system (Davis et al., 1995) , display major modifications in their expression in the comparison between normal urothelium and its corresponding cancerous tissue. The hyperexpression of the C locus in bladder cancer represents the most consistent alteration in HOX gene expression linked to a specific human solid tumour type so far described.
Results
We have analysed the expression of the entire HOX gene network in 15 pairs of bladder tissue biopsies, each pair from the same patient, and comprising, according to the pathologist, bladder cancer tissue (predominantly TCC) and adjacent normal urothelium (Figure 1 , left-hand side; Table 1 , samples 1-15). We have also tested the expression of specific HOX genes (the contiguous HOX C4, HOX C5 and HOX C6, and the paralogous group 11 genes, HOX A11, HOX C11 and HOX D11) in 15 individual bladder cancer samples (Table 1, samples 16-30) .
Analysis of HOX network gene expression in normal urothelium indicates that the network is generally active in the healthy bladder mucosa with 12 genes constitutively expressed, 16 genes heterogeneously active and 11 genes constitutively silent (Figure 1 , left-hand side). A characteristic expression pattern of the HOX gene network can be identified in different samples of normal bladder mucosa. The genes heterogeneously expressed in normal tissue are mostly located in the cervical region of the HOX A and HOX B loci and in the lumbosacral region of the HOX C and HOX D loci. By comparing the HOX network expressions of different loci in normal urothelium, we observe that the HOX C locus on chromosome 12, unlike the other loci, has most of its genes silent (six out of nine: HOX C4, HOX C5, HOX C6, HOX C9, HOX C11 and HOX C12), two genes always (HOX C8) or almost always (HOX C10) active and only one gene, HOX C13, heterogeneously expressed. The HOX C locus immediately appears unusual compared to its expression in normal bladder.
As far as bladder cancer is concerned, besides a hyperexpression of the whole HOX network, in locus HOX A we observe a significant increase in the frequency of cervical gene expression, which is heterogeneously active in the normal bladder (HOX A1 and HOX A2 together with HOX A4 and HOX A5). Furthermore, the HOX A3 gene, constitutively silent in normal urothelium becomes heterogeneously expressed in TCC. In contrast, in the lumbosacral region of locus A, the gene HOX A11, active in 60% of normal bladder biopsies, is active in only 6/30 (20%) of examined tumour samples ( Figure 1 ; Table 1 ). Moreover, in the 15 normal-tumour pairs examined, nine times HOX A11 becomes inactive in passing from normal to tumorous tissue. Only in two of the 15 pairs does the opposite happen, with HOX A11 inactive in normal urothelium becoming active in tumorous tissue from the same patient.
In the HOX B locus, when we compare normal and cancerous urothelium, we observe a less marked increase in the expression for the genes in paralogous groups 1-5 than in the HOX A locus. In particular, the HOX B2 gene, heterogeneously active (4/15) in healthy urothelium, increases its frequency of expression in tumorous samples (11/15). The HOX B3 gene, silent in normal urothelium, is now expressed in 4/15 tumour samples. No significant variations of expression are observed in the comparison of normal and tumorous bladder for paralogous groups 6-13.
The expression of the genes located in the HOX C locus seems to be profoundly modified in the comparison between healthy and cancerous urothelium: four out of six genes that are constitutively silent in normal bladder (HOX C4, HOX C5, HOX C6 and HOX C11) (Figure 2 ) are actively expressed in most bladder cancers. The HOX C4 gene inactive in normal urothelium becomes expressed in 11/15 paired tumorous biopsies ( Figure 2 ) and in 9/15 single tumorous biopsies (Table 1) . Therefore, the HOX C4 gene becomes active in 20/30 (60%) of tumorous samples, whereas it is silent in the normal urothelium. The HOX C5 gene is also silent in all the normal urothelia examined, but is actively expressed in all the paired tumorous biopsies (Figure 2 ) and in 11/15 of the single TCCs (Table 1) . Therefore, the HOX C5 gene is actively expressed in 26/30 (86%) of the tumorous samples analysed, whereas it is silent in normal urothelium. Moreover, in the four cases in which HOX C5 is silent in the tumorous biopsies, the adjacent HOX C4 gene is also silent, regardless of the histopathological characteristics of the biopsy tissue (Table 1) . Finally, as regards the block of genes adjacent to the 3 0 end of the HOX C locus, the HOX C6 gene (Figure 2 ) is always silent in normal bladder but active in 100% of the 30 cases (paired and single) of TCC examined. The paralogous group 11 HOX C gene, HOX C11, also displays substantial HOX genes and bladder cancer M Cantile et al alterations in its expression when passing from the complete absence of expression in normal urothelium to its activation in 24/30 (80%) of the tumorous samples examined (Figure 2 ; Table 1 ). Finally, the HOX C13 gene, on the 5 0 end of the HOX C locus, which is expressed in 6/15 (40%) of the samples of normal urothelium, becomes active in all the tumorous biopsies examined. The change in the expression of the HOX C locus in TCC is so extended along the locus as to suggest the possibility of chromosomal alteration (the HOX C locus is about 100 kb long) on the chromosome 12q13, as has been recently reported (Simon et al., 2002) .
The HOX D locus genes do not display significant changes in their expression in the comparison between normal and cancerous urothelium, with the exception of HOX D11 which is silent in normal urothelium but becomes heterogeneously expressed in 17/30 (57%) samples of TCC tested (Figure 2 ; Table 1 ).
Finally, we have compared the expression of the HOX genes on the 3 0 end of the HOX C locus (HOX C4, HOX C5 and HOX C6) and the paralogous group 11 genes (HOX A11, HOX C11 and HOX D11) with the histopathological features of the tumorous biopsies used in our analysis. The data reported in Table 1 indicate a lack of correspondence for the histological grade, stage, phenotype and p53 gene expression with respect to the altered expression of the HOX genes observed through our molecular analysis.
Discussion
In this paper, we have analysed the in vivo expression of the HOX genes in 15 pairs of normal-tumorous biospies obtained from patients with transitional cell carcinomas of the bladder and in 15 single samples of the same type of tumour. The results indicate that the HOX C locus, one of the four chromosomal locations on the HOX network, situated on chromosome 12q13.3, displays an unusual expression even in the samples of normal bladder. Unlike the expression of network genes located on the other loci (HOX A, B and D), where the constitutively active HOX genes are more numerous than (loci A and D) or equal in number to (locus B) those that are always silent, the constitutively inactive genes in the HOX C locus are much more numerous (six) than the single, always active gene (HOX C8). In TCC, where the expression of the whole HOX network generally tends to increase, we have observed dramatic variations in expression in the HOX C locus, as four of the six genes (HOX C4, HOX C5, HOX C6 and HOX C11), which are constitutively silent in normal tissue, become active in most of the bladder cancer samples analysed. Moreover, the paralogous group 11 HOX genes (HOX A11, HOX C11 and HOX D11), already involved during normal development in urogenital organogenesis (Davis et al., 1995) , also display remarkable variations of expression between normal urothelium and TCC. The HOX A11 gene, active in most normal bladder tissue, tends to become silent in cancer tissue. The HOX C11 gene, which is silent in normal urothelium, becomes active in almost all the TCC samples tested. Finally, the HOX D11 gene, always silent in normal bladder tissue, appears heterogeneously expressed in bladder cancer. These results suggest a major involvement of the HOX network and, in particular, of the HOX C locus and the paralogous group 11 genes in bladder cancer.
The physical location of the HOX C locus on chromosome 12q13 is within a chromosomal region recently described as amplified in bladder cancer (Simon et al., 2002) . This region contains (in addition to the entire HOX C locus) around 60 genes, including those which play a better documented oncogenic role such as murine double minutes (MDM2), cyclin-dependent kinase 4 (CDK4) and glioblastoma-associated oncogene (GLI).
The gene product of MDM2 controls both p53 and other cell cycle regulators, such as E2F1 (Jones et al., 1996) . It is known that HOX genes can interact with p53 (Cillo et al., 1995a) and that the HOX A5 gene transcriptionally regulates a series of genes including p53 (Raman et al., 2000) . So far, no direct interactions have been reported between HOX genes and MDM2.
Interactions between CDK4 and type D cyclins are crucial in the G1 phase of the cell cycle (Reed, 1997) . CDK4 can interact with homeobox-containing genes (Hu et al., 2001) . CDK4 mutations have been described in human melanoma (Wolfel et al., 1995) . HOX genes located at the 5 0 end of the HOX C locus (HOX C10, HOX C11, HOX C12 and HOX C13) are heterogeneously expressed in human melanoma populations with different metastatic ability .
Finally, GLI genes make up a family of zinc finger transcription factors, are homologous to the Kruppel segmentation gene of Drosophila and are involved in normal development (Walterhouse et al., 1993) as well as in glioma (Kinzler et al., 1987) and basal cell carcinoma (Nilsson et al., 2000) . The HOX and GLI networks therefore act in parallel during normal development. The locus C HOX genes and the GLI1 gene are adjacent on chromosome 12 and there are no existing data on one interacting with the other.
The alteration of the HOX C locus gene expression we observe seems to involve a much higher percentage of TCCs than the above-described gene amplification process reveals. Therefore, the molecular alteration of the HOX C locus might be an early event in urothelial carcinogenesis which, during tumour evolution, will be involved in a gene amplification process in a lower percentage of cases. Proof of the early molecular damage to the HOX C locus lies in the non matching of histopathological grade, stage, phenotype and TP53 gene expression with HOX gene expression in the tumour samples analysed (Table 1) .
Cytokeratins (CKs) are intermediate filament proteins whose function it is to maintain shape and cell integrity and to participate in cell-cell communication (Moll et al., 1982) . Around 20 different isotypes of CKs have been identified, the majority of which are expressed in epithelial cells and altered in their neoplastic transformation (Moll et al., 1988) . In bladder cancer, alteration of the expression of a series of CKs normally active in the urothelium, such as CK8, CK18 and CK 19, has been described, making it possible to suggest a distinction between TCCs through cytokeratin expression patterns (Moll et al., 1988) . Genes coding for the cytokeratins CK8 and CK18 are located on the chromosome 12q.13 along with the cytokeratin genes CK1, CK 3, CK 4, CK5, CK6A and CK6B (Yoon et al., 1994) physically contiguous to the 5 0 end of the HOX C locus, whose huge alteration in TCCs we have described.
In addition, at the 3 0 end of the HOX C locus and in the same physical contiguity, we find the genes for CK7 and the basic hair Keratin 1 and 6, transcriptionally regulated by the HOX C13 gene (Jave-Suarez et al., 2002) . Another group of cytokeratin genes is located on chromosome 17p21.3 (Lussier et al., 1990) in physical contiguity with the HOX B locus. In biology, the concept of common functions performed by physically and/or evolutionarily contiguous genes is gaining more and more support (Spitz et al., 2003) . During normal development, the paralogous group 11 HOX genes are involved in the formation of the posterior region, including the urogenital system (Hostikka and Capecchi, 1998) . In the urogenital system, the prominent expression of these genes is observed in the posterior urogenital sinus, which will generate the urethra, vagina and prostate (Hostikka and Capecchi, 1998) . Specific mutations in each of the paralogous group 11 Hox genes have been produced in mice, displaying more or less severe alterations on caudal structures (Small and Potter, 1993; Davis and Capecchi, 1994; Favier et al., 1994) . Double mutant mice for the Hox a11 and Hox d11 genes have been produced, displaying much greater alterations of the posterior body and the urogenital system than the single mutants (Davis et al., 1995) . The data we present allow us to hypothesize a role for paralogous group 11 HOX genes in the regulation of the cell phenotypes involved in bladder carcinogenesis, as we have already reported in kidney carcinomas (Cillo et al., 1992) and in Wilms' tumour (Cillo et al., 1995b) .
We have described the dramatic variations of locus C HOX genes as well as of paralogous group 11 HOX genes in bladder cancers. These results, once extended to a large series of cases in a high-throughput tissue analysis such as tissue microarray (Nocito et al., 2001) , may represent a useful clinical tool in the predictive oncology of bladder cancer.
Materials and methods

Specimens
Normal and malignant bladder tissue was obtained from non-selected patients operated at the Urology Department of our Medical School. During cystoprostatectomy, samples from non-necrotic bladder cancer tissue as well as intact normal urothelium from an area within a few centimetres of the tumour were taken. The tumour sample was split into two parts and analysed by the pathologist for diagnosis, tumour stage and grade according to the TNM system (UICC, 1997) ( Table 1) . Normal urothelium, obtained by sampling a superficial layer of bladder mucosa, was also split into two parts and analysed by the pathologist to exclude the presence of infiltrating stromal cells or displastic changes. The presence of more then a minimal amount of stromal contamination or dysplasia in normal urothelium justified the exclusion of both normal and corresponding cancer biopsies from RNA extraction. All samples of normal urothelium and bladder cancers were reviewed by a single pathologist. The other part of the samples was snap-frozen in liquid nitrogen and stored at À801 until used for RNA extraction. Isolated bladder cancer biopsies were obtained through transurethral resection and followed the same treatment as the cancer biopsies belonging to normal-tumour pairs. An overview of the histological and clinical data is given in Table 1 .
RNA extraction and analysis
Frozen tissues were pulverized with a blender. Total RNA was extracted by the guanidinium thiocyanate technique (Chirgwin et al., 1979) . Total RNA (4 mg) was subjected to cDNA synthesis for 1 h at 371C using the ''Ready to go You-Primer First-Strand Beads'' kit (Amersham Biosciences cod. 27-9264-01) in a reaction mixture containing 0.5 mg oligo-dT (Amersham Biosciences cod. 27-7610-01).
PCR amplification
PCR amplification of cDNA was performed in a reaction mixture (Pure Taq Ready to go PCR beads Amersham Biosciences cod. 27-9558-01) containing 4 ml of cDNA sample and different primer sets (20 p/mol each). The sense/anti-sense HOX primers for PCR were designed as previously reported (Cantile et al., 2003a, b) . The sense/anti-sense p53 primers for PCR were designed according to the following sequences: sense primer 5 0 -3 0 : AGTCTGTGACTTGCACGTACTCanti-sense 5 0 -3 0 : CCAGACCATCGCTATCTGAG, producing a 207 bp fragment. To prevent genomic DNA contamination, primer sense and anti-sense were designed to frame a sequence that crossed at least one intron on the genes. The coamplification of the specific HOX gene and human b-actin gene, as an internal control, was achieved using two primer sets in a single reaction mixture. We selected two pairs of b-actin primers to obtain amplified fragments with different molecular weights (149 and 433 bp), to be used alternatively in the coamplification reaction. Duplex-PCR products were separated by ethidium 1.2% agarose gel electrophoresis.
